CPDR is a comprehensive research program to study prostate cancer and prostate disease, CPDR was established in 1992 (Public Law 102-172). The program’s mission is fulfilled primarily through its three principal programs: (1) the Clinical Translational Research Center; (2) the Basic Science Research Program, and (3) the Tri-Service Multicenter Prostate Cancer Database to encompass its clinical research work with participating military medical centers.

The Clinical Translational Research Center

clinical researchA prostate cancer clinical trials center at Walter Reed National Military Medical Center (WRNMMC). Recognizing that too few men have participated in clinical trials in the past, this Center will make state-of-the-art research trials available to deserving military health beneficiaries. The Center is open to all beneficiaries worldwide.

Basic Science Research Program

basic sceince researchThe only free-standing prostate cancer research center in the U.S. This 20,000 square foot state-of-the-art basic science laboratory facility is attracting the best and brightest to study the disease. Using blood and tissues collected from volunteering military beneficiaries, the CPDR laboratory has amassed a large bank of prostate cancer specimens that are serving to unravel the genetics of the disease.

Tri-Service Multicenter Prostate Cancer Database

national database The largest, most comprehensive prostate cancer database in the United States. Involving the Army, Air Force, and Navy at multiple military medical centers, the program is a model for interservice cooperation and research collaboration. With approximately 26,000 prostate cancer survivors enrolled to date, the CPDR database is rapidly becoming a national resource.


The information provided on this web site is for informational purposes only and is not intended to replace medical advice. You should review the information carefully with your physician(s) before adopting any of this information into your current medical plan. CPDR provides clinical and research information that is complete and in accord with the standards in existence at the time of publication. However, CPDR does not warrant that the information contained herein is in every respect accurate or complete and CPDR is not responsible for any errors or omissions or for the results obtained from the use of this information. CPDR makes no representations or warranties with resect to any treatment, action, process or application of medication by any person following the information provided by CPDR. CPDR will not be liable for any damages arising from the use of this information.

The opinions and assertions contained herein are the private views of the author and are not to be construed as reflecting the views of the US Department or Defense.

Please consult with your doctor before adopting any of the information found on this site into your current healthcare plan.


CPDR Distinguished Guest Speaker

Dr. Annette Fenner

Chief Editor
Nature Reviews Urology

Presentation: "Editor’s Insights – the Nature of Urology"

Annette Fenner studied at Imperial College London, where she completed her medical degree and intercalated a BSc in Endocrinology and PhD in Reproductive Biology. During her PhD, she worked on hypothalamic peptides in the control of reproduction, with a particular focus on the role of kisspeptins. Bringing with her an interest in the field of sexual medicine, she joined the Nature Reviews Urology team as an Associate Editor in 2010, and was promoted to Chief Editor in 2011.

Date: 30 November 2015
Time: 11:00 AM - 12:00 PM
Location: CPDR Rockville, MD


WRNMMC UsToo! Newsletter

Read the November 2015 WRNMMC UsToo! Newsletter

Go to WRNMMC UsToo! Newsletter Archive


July 20, 2015

CPDR's GHI publication is featured in the latest MDLinx "Best of Oncology"


April 21, 2014

Biological and Genomic Differences of ERG Oncoprotein-Stratified Prostate Cancers from African and Caucasian Americans